In addition, three other HDAC inhibitors have been approved by the FDA, romidepsin, belinostat and panobinostat, which have primarily been used in multiple myeloma, peripheral T‐cell lymphoma (PTCL) and cutaneous T‐cell lymphoma.117. The gene discussed is HDAC9; the disease is plasma cell myeloma.